Jan. 28 at 6:11 PM
Biotech is waking up again. Capital is rotating back into platforms.
Cancer vaccines, mRNA, and immunotherapy are scaling. That needs better delivery tech. That’s where
$BIOV /
$BVAXF fits, alongside
$MRNA $BNTX $LLY.
When biotech runs, I’d rather own the plumbing early.